Immune-related adverse events with adjuvant anti-PD-1 therapy in high-risk resected melanoma: a single-center experience

Immune-related adverse events with adjuvant anti-PD-1 therapy in high-risk resected melanoma: a single-center experience

Saved in:

Bibliographic Details
Main Authors:	I. Csányi, C. Hánis, H. Ócsai, I. Németh, J. Oláh, R. Gyulai, E. Baltás
Format:	Article
Language:	English
Published:	Elsevier 2024-01-01
Series:	EJC Skin Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772611824001435
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Gastric Melanoma: Primary or Secondary Forms? 2 case reports
by: C. Hanis, et al.
Published: (2024-01-01)

Real‐Life Cohort of Patients With Resected High‐Risk Melanoma Treated by Adjuvant Anti‐PD1 Therapy
by: Liza Benzoni, et al.
Published: (2025-03-01)

Quality of life changes after electrochemotherapy: a prospective single-center analysis
by: Petra Rózsa, et al.
Published: (2025-05-01)

Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma
by: Diane van der Woude, et al.
Published: (2024-06-01)

Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment
by: Michael Weichenthal, et al.
Published: (2024-12-01)

Major Adverse Cardiovascular Events in Patients with Melanoma Receiving Immune Checkpoint Inhibitors
by: Juan I. Ruiz, et al.
Published: (2025-04-01)

Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)

Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation
by: Julia Forschner, et al.
Published: (2025-08-01)

Impact of Immune-Related Adverse Events on Melanoma Outcomes: A Comprehensive Analysis
by: Y. Ahmed, et al.
Published: (2024-01-01)

Adjuvant Therapy: Melanoma
by: Diwakar Davar, et al.
Published: (2011-01-01)

Adjuvant Anti–PD-1 Monotherapy Versus Observation for Stage III Acral Melanoma of the Sole: A Multicenter Retrospective Study in Japanese Patients
by: Shigeru Koizumi, et al.
Published: (2025-04-01)

Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany
by: S Wahler, et al.
Published: (2021-01-01)

Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies
by: Qing Zhang, et al.
Published: (2025-04-01)

Risk factors and outcomes of thyroid immune-related adverse events following PD-1/PD-L1 inhibitors treatment in a large tertiary Chinese center
by: Wenwen Gong, et al.
Published: (2025-07-01)

Real-world outcomes of adjuvant therapy in melanoma: an Italian referral center experience
by: G. Roccuzzo, et al.
Published: (2024-01-01)

Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled Analysis
by: Asma Dilawari, et al.
Published: (2025-05-01)

Perspectives of Targeting Autophagy as an Adjuvant to Anti-PD-1/PD-L1 Therapy for Colorectal Cancer Treatment
by: Nasrah ALKhemeiri, et al.
Published: (2025-05-01)

Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitors
by: Juan Chen, et al.
Published: (2024-07-01)

Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
by: Magdalena K. Zielińska, et al.
Published: (2025-02-01)

Efficacy and safety of adjuvant systemic therapies in trial non-eligible resected stages III and IV melanoma patients
by: Sarah Alsadiq, et al.
Published: (2025-05-01)

Sex, Age, and Previous Herpes Zoster Infection Role on Adverse Events Following Immunization with Adjuvanted Recombinant Vaccine
by: Maria Costantino, et al.
Published: (2025-02-01)

Endocrine adverse events of immune checkpoint inhibitors: results of a single-center study
by: E. V. Poddubskaya, et al.
Published: (2019-12-01)

An update on adjuvant systemic therapies in melanoma
by: Evangeline Samuel, et al.
Published: (2019-11-01)

Tyrosinase in melanoma inhibits anti-tumor activity of PD-1 deficient T cells
by: Rong Huang, et al.
Published: (2025-05-01)

Real-world outcomes for advanced melanoma in the adjuvant and unresectable setting: Single-center registry analysis
by: R. Staeger, et al.
Published: (2024-01-01)

PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
by: Qingya Song, et al.
Published: (2025-12-01)

Management of immune-related adverse events under PD-1/PD-L1 inhibitors: Insights from a Moroccan real-world experience
by: Inès Cherradi, et al.
Published: (2025-01-01)

NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors
by: Michael S. Chang, MD, et al.
Published: (2025-02-01)

Thermoresistant flagellin-adjuvanted cancer vaccine combined with photothermal therapy synergizes with anti-PD-1 treatment
by: Jayalakshmi Thiruppathi, et al.
Published: (2025-03-01)

Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma
by: Ikuan Sam, et al.
Published: (2025-03-01)

Residual Tumor Resection After Anti-PD-1 Therapy: A Promising Treatment Strategy for Overcoming Immune Evasive Phenotype Induced by Anti-PD-1 Therapy in Gastric Cancer
by: Hajime Matsuida, et al.
Published: (2025-08-01)

Predicting immune-related adverse events in patients with melanoma: the role of interleukin-7 rs16906115 polymorphism and lymphocyte dynamics
by: Fatma Pınar Açar, et al.
Published: (2025-06-01)

Hypercalcemia as an Immune-Related Adverse Event in a Patient Receiving Nivolumab and Ipilimumab for Metastatic Melanoma: A Case Report
by: Sam Plessers, et al.
Published: (2025-01-01)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
by: Yu Chen, et al.
Published: (2023-01-01)

Author Correction: Tyrosinase in melanoma inhibits anti-tumor activity of PD-1 deficient T cells
by: Rong Huang, et al.
Published: (2025-06-01)

Current treatment strategy for resectable scalp and neck melanoma
by: A. P. Polyakov, et al.
Published: (2021-08-01)

Associations between immune-related adverse events and the effectiveness of immunotherapeutic agents in advanced melanoma: A systematic review and meta-analysis
by: Jiayang Yu, et al.
Published: (2025-04-01)

Updated outcomes of AdjuMel study: real-world data in patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France
by: S. Dalle, et al.
Published: (2024-01-01)

Circulating immune landscape in melanoma patients undergoing anti-PD1 therapy reveals key immune features according to clinical response to treatment
by: Eleonora Sosa Cuevas, et al.
Published: (2024-12-01)

The clinical outcomes of adjuvant gemcitabine plus S-1 in resected pancreatic cancer: a single-center retrospective study
by: Kuan-Yu Tseng, et al.
Published: (2025-07-01)